Get the Stockscreener App
44.44
0.91%
0.40
After Hours:
43.81
-0.63
-1.42%
Veradermics Inc stock is traded at $44.44, with a volume of 243.73K.
It is up +0.91% in the last 24 hours and up +0.00% over the past month.
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
See More
Previous Close:
$44.04
Open:
$44.16
24h Volume:
243.73K
Relative Volume:
2.79
Market Cap:
$1.56B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+19.59%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$42.96
$45.78
1-Week Range:
$35.20
$45.78
52-Week Range:
$32.00
$45.78
Veradermics Inc Stock (MANE) Company Profile
Compare MANE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
44.44 | 1.54B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Veradermics Inc Stock (MANE) Latest News
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell – Company Announcement - Financial Times
Assessing Veradermics (MANE) Valuation After Recent Share Price Move And Persistent Pre Revenue Losses - Yahoo Finance
Veradermics completes enrollment in second pivotal phase 3 clinical trial of Vdphl01 for male pattern hair loss - marketscreener.com
Veradermics Completes Enrollment in 2nd Phase 3 Study of VDPHL01 for Male Pattern Hair Loss - marketscreener.com
Completion of VDPHL01 Phase 3 Enrollment for Male Pattern Hair Loss - Intellectia AI
Veradermics completes enrollment in phase 3 trials for hair loss drug - Investing.com
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss - Business Wire
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Four IPOs In One Week - Citeline News & Insights
A sign biotech is back? Four drugmakers go public, raising nearly $1 billion in all - statnews.com
Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering - BioSpace
Veradermics completes $294.8 million IPO with full underwriter option exercise - Investing.com
Veradermics CEO has a great hair day with 122% pop in IPO - Endpoints News
Hair regrowth biotech raises $256m in ‘upsized’ IPO - longevity.technology
Veradermics’ IPO raises $256M in stellar NYSE debut - Hartford Business Journal
Veradermics Raises $256 Million in Upsized Initial Public Offering - Pharmaceutical Executive
A cut above: Veradermics locks in $256M IPO and shares spike - Fierce Pharma
Veradermics announces pricing of upsized IPO - The Pharma Letter
Eikon, Veradermics close IPOs, as Salspera joins queue - pharmaphorum
Ropes Leads Hair-Loss Firm Veradermics' Upsized $256M IPO - Law360
Veradermics, Inc. (MANE): Dermatology Biotech Blasts Off, Eli Lilly and Wellington Anchor Hot IPO - Smartkarma
Baldness Biotech Veradermics Prices $256M IPO for Pivotal Tests of Pill for Hair Loss - MedCity News
Veradermics prices upsized IPO at $17 per share, raises $256.3 million - Investing.com Nigeria
Veradermics, Dermatology-Focused Biopharma Developing Extended-Release Oral Minoxidil for Pattern Hair Loss, Files for NYSE IPO - TradingView
Hair Loss Firm Veradermics Jumps 124% After $256 Million IPO - Bloomberg
No Revenue? No Problem. Biotech Targeting Hair Loss Doubles in Stock IPO. - Barron's
Soaring Veradermics IPO Shows Investor Interest In Hair-Loss Companies Isn’t Thinning - Crunchbase News
Veradermics stock soars 118% in NYSE debut after upsized IPO By Investing.com - Investing.com South Africa
Veradermics stock soars 118% in NYSE debut after upsized IPO - Investing.com
Veradermics stock surges on public debut (MANE:NYSE) - Seeking Alpha
Veradermics soars in NYSE debut after upsized $256.3 million IPO - TradingView
Veradermics opens at $34, IPO priced at $17 per share - TipRanks
Veradermics Shares More Than Double in NYSE Debut - marketscreener.com
Veradermics indicated to open at $20-$22, IPO priced at $17 - TipRanks
Veradermics IPO: $256.3M Raised for Biotech's Hair Restoration Therapy | 2026News and Statistics - IndexBox
Veradermics prices upsized IPO at $17 per share, raises $256.3 million By Investing.com - Investing.com South Africa
Veradermics claims year's second IPO in upsized $256M offering - FirstWord Pharma
Veradermics Raises $256.3 Million in Upsized IPO, Valuing Firm at $596 Million - SSBCrack News
Hair Loss Biopharma Firm Veradermics Raises $256 Million in IPO - ubirataonline
Veradermics IPO Pops Above Range as Eli Lilly Lines Up a 5% Stake Play - TechStock²
Veradermics Raises $256M in IPO to Advance Hair Loss Treatments - Meyka
Veradermics Prices Upsized $256.3 Million Initial Public Offering - marketscreener.com
Veradermics Prices Upsized IPO at $17, Expected to Raise $256.3M - Intellectia AI
Hair loss pill developer Veradermics raises $256.3M in upsized IPO (MANE:Pending) - Seeking Alpha
Hair loss pill developer Veradermics seeks up to $534M valuation in US IPO - MSN
MANE IPO NewsHair loss biotech Veradermics prices upsized IPO at $17, above the range - renaissancecapital.com
Hair Loss Biopharmaceutical Company Veradermics Secures $256 Million Through IPO - Bitget
Veradermics Prices Upsized IPO at $17 per Share - Intellectia AI
Veradermics prices upsized IPO at $17 per share, raising $256.3 million By Investing.com - Investing.com South Africa
Veradermics prices upsized IPO at $17 per share, raising $256.3 million - Investing.com UK
Veradermics says it prices of upsized initial public offering at $17 per share - marketscreener.com
Veradermics Inc Stock (MANE) Financials Data
There is no financial data for Veradermics Inc (MANE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):